{
  "id": 1768146601862,
  "seqId": 77,
  "title": "Mastering Corneal Surface Disorders: TSPK, RCES, and PED",
  "summary": "An exhaustive clinical guide to diagnosing and managing Thygeson’s Superficial Punctate Keratopathy, Recurrent Corneal Erosion Syndrome, and Persistent Epithelial Defects. This resource details etiology, clinical presentation, and a spectrum of treatments from conservative lubrication to advanced surgical grafting.",
  "date": "2026-01-11T15:50:01.862Z",
  "data": {
    "title": "Mastering Corneal Surface Disorders: TSPK, RCES, and PED",
    "summary": "An exhaustive clinical guide to diagnosing and managing Thygeson’s Superficial Punctate Keratopathy, Recurrent Corneal Erosion Syndrome, and Persistent Epithelial Defects. This resource details etiology, clinical presentation, and a spectrum of treatments from conservative lubrication to advanced surgical grafting.",
    "summary_illustration": "<svg viewBox='0 0 100 100' xmlns='http://www.w3.org/2000/svg'><circle cx='50' cy='50' r='45' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='2'/><path d='M25 50 Q 50 20 75 50 Q 50 80 25 50' fill='none' stroke='hsl(215, 90%, 45%)' stroke-width='3'/><circle cx='50' cy='50' r='10' fill='hsl(215, 90%, 45%)' fill-opacity='0.2'/><path d='M40 45 L45 45 M55 55 L60 55 M42 58 L47 58' stroke='hsl(215, 90%, 45%)' stroke-width='1.5' stroke-linecap='round'/></svg>",
    "sections": [
      {
        "title": "Thygeson’s Superficial Punctate Keratopathy (TSPK)",
        "icon": "visibility",
        "type": "mindmap",
        "layout": "full_width",
        "color_theme": "blue",
        "content": {
          "center": "TSPK Overview",
          "branches": [
            "Rare condition",
            "Arises in young adulthood",
            "Duration: 1mo to 24y",
            "Idiopathic aetiology (viral suspected)",
            "Bilateral, but often asymmetric"
          ]
        }
      },
      {
        "title": "TSPK: Clinical Features & Diagnostics",
        "icon": "clinical_notes",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "blue",
        "content": [
          "Bilateral recurrent FB sensation, photophobia, and tearing.",
          "Coarse, stellate grey-white epithelial opacities.",
          "Presentation in a white, quiet eye.",
          "Opacities appear slightly elevated.",
          "Classically non-staining with fluorescein or lissamine green.",
          "There may be a slight epithelial haze."
        ]
      },
      {
        "title": "TSPK: Treatment Protocol",
        "icon": "medication",
        "type": "process",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Topical corticosteroids (e.g. fluorometholone 0.1%): rapidly tapered.",
          "Maintenance dose (even 1×/wk) may be required to prevent episodes.",
          "Consider therapeutic CL: for vision and comfort."
        ]
      },
      {
        "title": "References: TSPK Foundation",
        "icon": "menu_book",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "3. Thygeson P. Superficial punctate keratitis. J Am Med Assoc. 1950;144:1544–9. \n4. Nagra PK et al. Thygeson’s superficial punctate keratitis: ten years’ experience. Ophthalmology. 2004;111:34–7."
      },
      {
        "title": "Recurrent Corneal Erosion Syndrome (RCES)",
        "icon": "history",
        "type": "mindmap",
        "layout": "full_width",
        "color_theme": "purple",
        "content": {
          "center": "RCES Definition",
          "branches": [
            "Failure of epithelial to BM readhesion",
            "Recurrent episodes of spontaneous breakdown",
            "Diagnosis may be made on history alone (if features resolved)"
          ]
        }
      },
      {
        "title": "RCES Risk Factors",
        "icon": "warning",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "Sharp trauma.",
          "Anterior Corneal Dystrophies (Epithelial BM dystrophy, Reis–Bucklers dystrophy).",
          "Stromal dystrophies.",
          "Post-keratoplasty.",
          "Diabetes.",
          "Dry eye.",
          "Ocular rosacea."
        ]
      },
      {
        "title": "RCES Clinical Features & Pathology",
        "icon": "microscope",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "purple",
        "content": [
          "Recurrent severe pain and photophobia, usually on opening eyes after sleep.",
          "Aggravated by blinking; resolves within hours.",
          "History of corneal trauma (often forgotten).",
          "Epithelial irregularities or loose epithelium (without staining) or frank defects.",
          "Underlying disease signs: microcysts, maps, dots, fingerprints, or stromal changes.",
          "Severe cases: lid oedema, ciliary injection, extreme photophobia, and reduced vision.",
          "NB: May predispose to infection.",
          "Pathology: Abnormal adhesion, hemidesmosome defects, BM thinning/reduplication.",
          "Excessive MMPs result in enzymatic degradation of adhesion complexes."
        ]
      },
      {
        "title": "RCES Conservative Treatment",
        "icon": "medical_services",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Topical Lubricants: Carmellose 0.5–1% hourly (day), Oc Lacri-Lube® (nocte).",
          "Cycloplegia: e.g. cyclopentolate 1% 2×/d for comfort.",
          "NSAID: e.g. ketorolac 3×/d for comfort.",
          "Duration: Lubricants must continue for minimum 6wk post-resolution.",
          "Therapeutic CL: Extended-wear silicone hydrogel or high-water content hydrogel."
        ]
      },
      {
        "title": "Tetracyclines in RCES",
        "icon": "pill",
        "type": "plain_text",
        "layout": "half_width",
        "color_theme": "green",
        "content": "Doxycycline 50–100mg 1×/d for 3mo, or oxytetracycline 250mg 2×/d for 3mo, or Periostat® 20mg 1x/d. These inhibit MMP activity and promote epithelial stability."
      },
      {
        "title": "RCES Treatment Contraindications",
        "icon": "block",
        "type": "red_flag",
        "layout": "full_width",
        "color_theme": "red",
        "content": [
          "Tetracyclines are contraindicated in children under 12.",
          "Tetracyclines are contraindicated in pregnant or breastfeeding women.",
          "Tetracyclines are contraindicated in hepatic or renal impairment.",
          "Alternative for children 8-12y: Erythromycin 250mg 2x/d.",
          "Alternative for children 2-8y: Erythromycin 125mg 2x/d."
        ]
      },
      {
        "title": "RCES Surgical Interventions",
        "icon": "architecture",
        "type": "table",
        "layout": "full_width",
        "color_theme": "purple",
        "content": {
          "headers": [
            "Procedure",
            "Technique/Details"
          ],
          "rows": [
            [
              "Mechanical Debridement",
              "Break away non-adherent grey epithelium with moistened cotton bud/sponge under anaesthesia; use post-procedure therapeutic CL + topical chloramphenicol 0.5% 4×/d for 1wk."
            ],
            [
              "Alcohol Delamination",
              "Promotes stromal smoothing. 4–5 drops of 18% alcohol in a corneal well for 30–40s; drain; then debride entire corneal epithelium with cotton-tipped applicator."
            ],
            [
              "Excimer Laser PTK",
              "Consider for refractory or severe cases of RCES."
            ],
            [
              "Anterior Stromal Micropuncture",
              "For cases outside visual axis. Performed at slit-lamp or theatre; uses bent 25g needle to create packed micropunctures through epithelium and Bowman’s layer."
            ]
          ]
        }
      },
      {
        "title": "Persistent Epithelial Defects (PED)",
        "icon": "emergency",
        "type": "mindmap",
        "layout": "full_width",
        "color_theme": "red",
        "content": {
          "center": "PED Definition",
          "branches": [
            "Failed to heal within a 2wk period",
            "Failure of mechanisms promoting epithelialization",
            "Disassembly of hemidesmosomes",
            "Degradation of Bowman’s layer and stroma",
            "Disruption of protective corneal microenvironment"
          ]
        }
      },
      {
        "title": "PED Risk Factors",
        "icon": "priority_high",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "yellow",
        "content": [
          "Neurotrophic corneas.",
          "Limbal stem cell deficiency (e.g. chemical injury, aniridia).",
          "Immune-mediated ocular surface disorders (Atopic keratoconjunctivitis, OcMMP, SJS, Peripheral ulcerative sclerokeratitis)."
        ]
      },
      {
        "title": "PED Multi-Phase Treatment",
        "icon": "healing",
        "type": "key_point",
        "layout": "half_width",
        "color_theme": "green",
        "content": [
          "Must consider Healing Phase and Maintenance Phase (prevention).",
          "Topical: Oc chloramphenicol 1% with double pad.",
          "Topical Lubricants: Carmellose 0.5–1% (hourly), Oc paraffin (nocte), sodium hyaluronate (4×/d).",
          "Inflammation: Topical steroids (± systemic steroids/immunosuppression for OcMMP, gPA).",
          "Severe cases: Serum eye drops.",
          "Systemic: Doxycycline 100mg 1×/d, ascorbic acid 1g 2×/d.",
          "Contact Lenses: Silicone hydrogel, high-water content hydrogel, or gas-permeable scleral CL.",
          "Lid procedures: Botox-induced or surgical tarsorrhaphy; punctal plugs; punctal occlusion.",
          "Grafting: AM transplant, LESC transplantation, Gunderson flap, buccal mucous membrane graft."
        ]
      },
      {
        "title": "Role of Amniotic Membrane (AM) Transplantation",
        "icon": "layers",
        "type": "plain_text",
        "layout": "full_width",
        "color_theme": "blue",
        "content": "Box 7.5: Reserved for cases where conservative measures (lubricants, CL, autologous serum) fail and/or when Bowman’s layer is lost. AM acts as a BM substrate for epithelial cell migration. Effects are independent of technique (patch, bandage, or overlay)."
      },
      {
        "title": "Developments in Ocular Lubricants",
        "icon": "science",
        "type": "table",
        "layout": "full_width",
        "color_theme": "green",
        "content": {
          "headers": [
            "Agent",
            "Properties & Mechanism"
          ],
          "rows": [
            [
              "CMC (Carmellose)",
              "Improved surface retention; cytoprotective."
            ],
            [
              "Sodium Hyaluronate",
              "Cytoprotective; promotes hemidesmosome formation; ligand binding to CD44 (expressed during inflammation); plays role in wound healing and lubrication."
            ],
            [
              "P2y2 Receptor Agonists",
              "e.g. Diquafosol sodium (EMA pending). Elevates intracellular calcium; stimulates water and mucin secretion from conjunctival/goblet cells."
            ],
            [
              "Mucin Secretagogue",
              "e.g. Rebamipide 2% (EMA pending). Increases endogenous PGE2/I2; promotes mucin; free radical scavenger; wound healing; anti-inflammatory."
            ]
          ]
        }
      },
      {
        "title": "Summary of Novel Agents",
        "icon": "new_releases",
        "type": "remember",
        "layout": "full_width",
        "color_theme": "purple",
        "content": {
          "mnemonic": "CMC & HA",
          "explanation": "CMC (Carmellose) for retention/cytoprotection. HA (Hyaluronic Acid) for CD44 binding, hemidesmosome formation, and ubiquitous ECM wound healing."
        }
      }
    ]
  },
  "chapterId": "cornea"
}